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Background: Early detection of cystic ﬁbrosis (CF) by newborn screening (NBS) reduces the rate of avoidable complications. NBS protocols vary
by jurisdiction and the cost effectiveness of these different protocols is debated.
Objective: To compare the cost effectiveness of various CF NBS options.
Methods: A Markov model was built to simulate the cost effectiveness of various CF-NBS options for a hypothetical CF-NBS program over a
5-year time horizon assuming its integration into an existing universal NBS program. NBS simulated options were based on a combination of tests
between the two commonly used immunoreactive trypsinogen (IRT) cutoffs (96th percentile and 99.5th percentile) as ﬁrst tier tests, and, as a
second tier test, either a second IRT, pancreatic-associated protein (PAP) or CFTR mutation panels. CFTR mutation panels were also considered as
an eventual third tier test. Data input parameters used were retrieved from a thorough literature search. Outcomes considered were the direct costs
borne by the Quebec public health care system and the number of cases of CF detected through each strategy, including the absence of screening
option.
Results: IRT–PAP with an IRT cutoff at the 96th percentile is the most favorable option with a ratio of CAD$28,432 per CF case detected. The
next most favorable alternative is the IRT1–IRT2 option with an IRT1 cutoff at the 96th percentile. The no-screening option is dominated by all
NBS screening protocols considered. Results were robust in sensitivity analyses.
Conclusion: This study suggests that NBS for cystic ﬁbrosis is a cost-effective strategy compared to the absence of NBS. The IRT–PAP newborn
screening algorithm with an IRT cutoff at the 96th percentile is the most cost effective NBS approach for Quebec.
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Cystic fibrosis (CF) represents one of the most common and
disabling diseases in the Caucasian population [1,2]. In Canada,⁎ Corresponding author at: Département de médecine sociale et préventive,
Faculté de Médecine, Pavillon Ferdinand-Vandry, Université Laval, 1050
avenue de la médecine, Local 2432 Québec (QC) G1V 0A6, Québec, Canada
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Pub
http://dx.doi.org/10.1016/j.jcf.2013.10.012.lishedits incidence is estimated approximately at 1/3600 live births
[3] and 1/2500 in the province of Quebec [4].
With the advent of new treatment protocols and nutritional
support, most children with CF live to adulthood, with a median
age of survival of 48.1 years in Canada [5]. However, age at initial
CF diagnosis remains a major problem. Indeed, in the absence
of NBS, the median age at initial diagnosis is approximately
7 months while the mean age is 3.8 years, usually followingby Elsevier B.V. All rights reserved.
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[5,6].
Early detection of CF, i.e. before the appearance of the
first symptoms, has a beneficial effect on the evolution of the
disease by allowing earlier preventive treatment and follow-up
[2,7,8]. It has been shown that a diagnosis made before 2 months
of life is associated with improved nutritional status, better
growth, fewer hospitalizations and a decreased rate of complica-
tions throughout infancy, childhood, and adolescence, and better
cognitive functions [9–11]. Furthermore, early diagnosis and
treatment are believed to reduce expenses and parental anxiety
associated with failure to thrive and other symptoms [8].
Research has showed the potential benefits of early diagnosis
and treatment of CF through NBS. In a retrospective UK cohort,
Sims et al. [14] showed that the cost of therapy for patients
diagnosed through a NBS program (31 CFTR mutation panel)
was significantly lower (60–400%) than the costs of therapy
of clinically diagnosed patients of the same age-range. The
difference was attributed to lower treatment costs and reduced
hospital admissions for invasive therapies. Indirect costs and
disruption of family life were also expected to be lower among
screened infants.
As a result, NBS for CF has been proposed as a useful
approach to improve the quality of life of patients and their family
and has been promoted by several Genetic Societies including the
American College of Medical Geneticists, the American College
of Obstetricians and Gynecologists [8,12,13], as well as by the
USCenter for Disease Control [2]. Since these recommendations,
all US States have initiated CF NBS programs. In Canada, as
of 2013, five provinces (Alberta, British-Columbia, Manitoba,
Ontario and Saskatchewan) have implemented a NBS program
for cystic fibrosis [4,5].
One of the reasons that some jurisdictions in Canada
have delayed implementing a screening program is the lack of
information regarding the most cost/effective screening strategy
among the many existing options. Indeed, in spite of the many
cost effectiveness studies that have shown that CF NBS is cost
effective, no study has compared all together the different
screening algorithms that are realistically implementable. Also,
no study has tested various immunoreactive trypsinogen
(IRT) cutoffs as a first tier test with or without the different
CFTR mutation panels commonly used [14–17]. In addition to
identifying the optimal screening strategy, our study aims to
compare the cost effectiveness of 20 NBS algorithms using two
cutoffs (96th percentile and 99.5th percentile) of IRT as first
tier, varying the CFTR mutations panels, and comparing these
algorithms to the no-screening option.
2. Methods
2.1. Overview
A Markov decision model was built using the Clumeq
supercomputer network-running SCHNAPS platform [18–20] to
simulate the cost effectiveness of 20 CF-screening strategies and
to compare these strategies to the current situation (absence of
universal CF neonatal screening) in the Quebec public health caresetting. Comparisons were made for a hypothetical CF NBS
program spanning over 5 years and targeting newborns in the
province of Quebec [21]. We assumed that this screening program
would be integrated into the existing Quebec NBS program [22].
Outcomes considered were the direct costs borne by the Quebec
universal health care system and the number of CF cases detected.
2.2. Modeling
The simplified model structure is presented in Fig. 1. The
model, divided into cycles of 1 year each, has two starting
branches: 1) “Absence of NBS strategy” and 2) “NBS strategy”.
The model assumed a CF incidence of 1 in 2500 newborns (with
86 000 births, 35 CF cases are expected each year) [4]. The
model excludes those diagnosed clinically with ameconium ileus
(MI) as they would have been diagnosed at birth even in the
absence of neonatal screening [16,23].
Under “Absence of NBS”, newborns have an annual
probability of being diagnosed with CF based on symptoms
or a family history. These probabilities were modeled according
to data from the Quebec patients of the Canadian Cystic
Fibrosis Patient Data Registry (CPDR) [24]. This population
consists of 174 children with CF without MI who were born
since the year 2000. The model considered also that 75 (50–100)
sweats tests were performed in children without CF for each child
with a diagnosed CF [25]. This average estimate is similar to the
one observed in Quebec according to data recently published by
the QuebecNational Institute of Public Health from an analysis of
data from laboratories that perform sweat tests [4], and which is
around 72 sweat tests per child with CF.
Under “NBS strategy”, screening is proposed to all newborns.
As we assumed that a screening programwould be integrated into
the existing neonatal newborn screening program for genetic
diseases our model considered a similar screening coverage rate
of 99% of all newborns [22]. Newborns that were not screened
because their parents declined screening have the same
probability of being diagnosed clinically as those in the “Absence
of NBS strategy” option. When parents accept NBS, cases of CF
are detected according to the performance of the test used
(sensitivity and specificity). The model considered the compli-
ance rate for recall samples if a second IRT is required [16]. We
made the assumption that cases of CF would be detected within
the first three months in the screening options. For missed cases,
we assumed the same probability of being diagnosed clinically as
for those in the “Absence of NBS strategy” option.
In addition, we assume that if a child with CF is diagnosed, he
is followed in a CF specialized center from that point on. Each
year, this child has a probability of developing CF-associated
complications that lead to medical visits and hospitalizations.
Children with CFwho did not yet receive a diagnosis of CFmight
also experience CF-associated complications but with a higher
probability compared to those already diagnosed [9,26–28].
In all options, there is a probability at the end of each year
cycle that the child (with or without CF) has died. Because the
survival of children with CF under 5 years of age in Quebec
and Canada has been of approximately 100% over the last
decade according to the CPDR, we attributed to all children
Fig. 1. Decision model.
Table 1
Screening protocols.
Strategy Description
IRT_IRT Newborns with IRT1 above the cut-off used (96th or 99.5th)
are recalled for a second IRT. If the second IRT is N70 ng/
ml, newborn is referred for sweat test.
IRT_IRT_DNA Newborns with IRT1 above the cut-off used (96th or 99.5th)
are recalled for a second IRT. If the second IRT is N70 ng/
ml, newborn is referred for DNA-based CFTR mutation
analysis (25- or 43-mutation panel). If one or two mutations
are found, newborn is referred for sweat test.
IRT_DNA DNA CFTR mutation analysis (25- or 43-mutation panel) is
done for newborns with IRT1 above the cut-off used (96th or
99.5th). If at least one mutation is found, newborn is referred
for sweat test.
IRT_DNA_IRT DNA CFTR mutation analysis (25- or 43-mutation panel) is
done for newborns with IRT1 above the cut-off used (96th or
99.5th). If at least one mutation is found or if no mutations
are found but IRT1 is N99.9th percentile, newborn is referred
for sweat test.
IRT_PAP PAP test is done for newborns with IRT1 above the cut-off
used (96th or 99.5th). The result is positive if PAP test is
N1.8 ng/ml if the first IRT is N96th percentile or 1 ng/ml if
the first IRT is N99.5th percentile. Newborn is then referred
for sweat test.
IRT_PAP_DNA PAP test is done for newborns with IRT1 above the cut-off
used (96th or 99.5th). The result is positive if PAP test is
N1.8 ng/ml if the first IRT is N96th percentile or 1 ng/ml if
the first IRT is N99.5th percentile. Thereafter, DNA CFTR
mutation analysis (25- or 43-mutation panel). If at least one
mutation is found, newborn is referred for sweat test.
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which is an estimate of the average death risk based on age
according to data from the Quebec Institute of Statistics. In
sensitivity analyses, we used 5-year survival rates of 95% and
98% for children with CF assuming the same death probability
each year over the 5 years.
The input parameters are presented in Table 2. They are
based on published data, Quebec data extracted from the CPDR
as well as on experts' opinion. Parameters were modeled in order
to reflect the event probabilities in screened and unscreened
children with CF.
2.3. Newborn screening options
Screening algorithms are presented in Table 1. For all
screening algorithms, the model takes into account the
compliance rates at each screening step. For the first tier test
(IRT1), the model assumed a coverage rate of 99%, similar to
that of the existing Quebec newborn screening program for
genetic diseases [22]. The model considers, for all screening
algorithms that include the DNA analysis, the probability
of accepting genetic counseling as well as the probability of
consent to a DNA test [15,29].
2.4. Costs
Direct medical costs that were considered related to the
screening and treatment of cases of CF over a 5 year time horizon
under the perspective of the Quebec public health care system.
The costs of screening included the cost of the tests (IRT, PAP,
DNA, and sweat test), genetic counseling for the pre-and post
DNA testing options, and the physician fees for the tests'
interpretation. The costs of disease management included the
cost of medical visits, hospitalizations, laboratory, imaging and
electrophysiological tests, medications (antibiotics, corticoste-
roids, etc.) and special diets (vitamins, pancreatic enzymes,oxygen). Quantification of medical and paramedical services
used by CF infants was estimated using data from children with
CF without MI included in the CPDR database. Services used
before clinical diagnosis of CF were estimated from data of 44
Quebec children diagnosed before 5 years of age and for whom
data on services used were available. Quantification of services
after clinically diagnosis was estimated using data of 174 Quebec
patients of the CPDR born since the year 2000. As NBS for CF
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used by children diagnosed through NBS was estimated using
data from 126 children with CF originating from Alberta,
Saskatchewan, British-Columbia and Ontario, provinces that
have already implemented the NBS for CF.
All unit prices are Quebec public provincial average prices
calculated from governmental databases. The lowest reimburs-
able price for medications by the provincial public insurance
scheme RAMQ (RAMQ, Manuel des pharmaciens) [30] and
the average price paid by the RAMQ to physicians were
considered (RAMQ, manuel des médecins spécialistes) [20].
Unit prices for activity centers were calculated using the
Quebec financial and operational data base (SIFO). This was
applied to non-medical services, including ancillary services.
Provincial technical units were used for laboratory and imaging
tests to calculate their unit prices. All SIFO unit prices were
over-headed using the direct approach in order to take into
consideration the support activity centers [31]. As the PAP
assay is not available in Canada, its cost was estimated from the
documentation provided by a scientific adviser from a French
biotechnology company (Dynabio), which manufactures and
markets the PAP assays.
The fiscal year 2011–2012 was used to calculate all costs.
Costs were discounted at a rate of 3%. Detailed estimates of
costs used in the model are presented in Table 2.
2.5. Sensitivity analyses
Univariate and multi-way sensitivity analyses were per-
formed using the parameters suspected to have an impact on
outcomes as detailed in Table 2. One-way sensitivity analysesTable 3
Base case scenario results.
Option Total costs Total cases de
over 5 years a
IRT96_PAP 4 606 040 162
IRT96_IRT 4 705 345 164
IRT96_PAP_DNA_43mut 4 757 684 162
IRT96_PAP_DNA_25mut 4 760 827 161
IRT99.5_IRT 4 846 455 157
IRT96_IRT_DNA_43mut 4 864 426 164
IRT96_IRT_DNA_25mut 4 916 765 164
IRT99.5_DNA_43mut 4 949 418 162
IRT99.5_IRT_DNA_43mut 4 967 856 157
IRT99.5_DNA_43mut_IRT 4 979 282 162
IRT99.5_DNA_25mut_IRT 4 986 294 162
IRT99.5_DNA_25mut 5 001 776 162
IRT99.5_PAP 5 017 831 155
IRT99.5_IRT_DNA_25mut 5 019 528 156
IRT99.5_PAP_DNA_43mut 5 083 014 154
IRT99.5_PAP_DNA_25mut 5 134 686 154
IRT96_DNA_43mut 7 549 282 169
IRT96_DNA_25mut 7 611 016 168
IRT96_DNA_43mut_IRT 7 851 878 169
IRT96_DNA_25mut_IRT 7 858 894 169
Absence of NBS 8 646 422 152
IRT96 = IRT above 96th percentile; IRT99.5 = IRT above 99.5th percentile.
a Based on an estimate of 174 children born with CF over the ﬁve-year period, ex
b Dominated strategies are those that were found to be less efﬁcacious and more e
effectiveness ratio that is greater than that of the next, more effective, and more expwere performed to evaluate the eventual impact of each single
parameter on the results. We tested the minimum and the
maximum (from the 95% confidence intervals) value for
each of these variables. Subsequently, using Monte Carlo
simulations, multi-way probabilistic sensitivity analyses were
performed in which all parameters above mentioned were
varied concomitantly taking into account their distribution
function. We assumed that event probabilities followed a beta
distribution, that costs followed a gamma distribution while
relative risks were assumed to have a log-normal distribution
[47].
2.6. Validation
The model and simulation data were validated by three
CF experts (PD, LL, and AML). Data produced were then
validated by comparison with expected data (such as the
number of cases of CF diagnosed according to the algorithm
performances, number of expected confirmation tests, mortality
rates per age, CF hospitalization rates). For example, for a time
horizon of 5 years, our model predicted 174 ± 2 cases
(CI, 95%) of cystic fibrosis for an expected number of cases
of CF of 173. For an expected number of clinically diagnosed
cases of CF of 154 at the end of year 5, our model predicted
152 ± 2.5 cases of CF.
2.7. Ethics Committee
This project was approved by the Research Ethic Committee
of Laval University (Approbation no. 2011-135) in order to
access the Canadian CF Patient Registry.tected Cost/CF case detected Cost per additional
CF case detected
28 432 –
28 691 49 653
29 368 Dominated b
29 570 Dominated
30 869 Dominated
29 661 Dominated
29 980 Dominated
30 551 Dominated
31 642 Dominated
30 736 Dominated
30 779 Dominated
30 875 Dominated
32 373 Dominated
32 176 Dominated
33 006 Dominated
33 342 Dominated
44 670 406 278
45 303 Dominated
46 460 Dominated
46 502 Dominated
56 884 Dominated
cluding those diagnosed clinically with a meconium ileus.
xpensive than another strategy (strict dominance) or to have an incremental cost
ensive alternative (extended dominance).
Table 2
Model input parameters and costs.
Parameter Baseline Sensitivity analysis Reference
Number of newborns per year 2011 87221 [21]
2012 86755
2013 86106
2014 85872
2015 86080
Probability of being clinically diagnosed
according to age, %
0–1 year 70.4 [24]
1–2 years 11.7
2–3 years 9.4
3–4 years 4.0
4–5 years 2.2
N5 years 2.3
Annual CF incidence 0.0004 0.0006–0.00025 [4]
CF newborns with meconium ileus, % 15 10–20 [4]
IRT1 sensitivity (cutoff 96th), % 96.2 92–98 [2,16,17,32,33]
IRT1 sensitivity (cutoff 99.5th), % 80 78–85 [16,33–38]
Sensitivity IRT2,% 92 80–95 [15,17]
Specificity IRT2,% 94 90–95
Sensitivity DNA 25-mutation panel, % 97 95–100 [17,38]
Sensitivity DNA 43-mutation panel, % 99 95–100 [38]
Specificity DNA, % 99.99 95–100 [36,38,39]
Sensitivity PAP, % 85.7 75–95 [40–42]
Specificity PAP 99.991 95–100
Parents consenting to NBS, % 99 95–100 [22]
Consenting for genetic counseling, % 90 50–100 [15]
Parental consent for DNA testing
(conditional to acceptation of genetic counseling), %
50 50–100 [15]
Adherence to second IRT testing
(conditional to positive first IRT), %
90 90–100 [16]
NBS Visits 6 4–8 [24]
Hospitalization Probability 0,2 0.1–0.25
Number 1.1 1–2.2
Length of stay 8 6–10
Absence of NBS (before diagnosis) Visits 5 3–7
Hospitalization Probability 0.72 0.51–0.90
Number 1.6 1–3.1
Length of stay 9.14 5–13
Absence of NBS (after diagnosis) Visits 5 3–5
Hospitalization Probability 0.58 0.40–0.70
Number 1.3 1–2.6
Length of stay 9.35 6–12
Cost IRT1, CAD$ 2.65 1–5 [43]
Cost IRT2, CAD$ 20.65 19–23 [43]
Cost DNA multi-mutation analysis, CAD$ 315.5 100–500 [43]
Sweat test, CAD$ 218.4 150–300 [43]
PAP, CAD$ 10 5–15 [44]
Genetic counseling cost, CAD$ 124.4 100–200 [20]
CF hospitalization cost, CAD$ 1912/day 1200–2700 [45]
Clinic visits cost (including physician fees), CAD$ 128.73/visit 100–150 [20,24]
Lab tests (chest X-ray, pulmonary function test, microbiology,
blood/urine tests), CAD$
410.223/visit 350–500 [24,46]
Outpatient medications (oral and inhaled antibiotics,
inhaled and oral corticosteroids, pancreatic enzymes,
bronchodilatators, vitamins) + pharmacist fees, CAD$
13740.02/year 10000–20000 [24,30,46]
Home IV treatment, CAD$ 72.14/day 50–110 [24,46]
Oxygen therapy, CAD$ 74.33/day 50–110 [24,46]
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3.1. Base case scenario
Baseline results are presented in Table 3. All NBS options
are less costly than the absence of NBS. In terms of costs,IRT_PAP and IRT_IRT with an IRT cutoff at the 96th
percentile are the less costly options. Options that include a
DNA analysis as a second tier test for an IRT cutoff at the 96th
percentile are the most expensive options.
In terms of number of cases detected, all screening strategies
are more effective than the absence of screening. The most
272 L. Nshimyumukiza et al. / Journal of Cystic Fibrosis 13 (2014) 267–274effective options are those that include a DNA test (25- or
43-mutation panels) as a second tier test after a first positive
IRT using a cutoff at the 96th percentile. In a time horizon
of 5 years, a NBS program is predicted to detect up to 17
additional cases of CF, i.e. ≈4 cases per year compared to the
absence of NBS for a population of 86000 newborns per year.
However, even if there is a difference in cases detected by NBS
between the different algorithms, we find that, in the end, the
difference between these screening options in terms of the total
number of cases diagnosed after a 5-year period is small.
For example, the IRT96_DNA_25mut strategy detects 17 more
cases of CF through NBS than IRT96_IRT, but the difference in
total cases of CF diagnosed after a 5-year period between these
two strategies is only 4 cases.
In term of cost per case detected, our results show that the
absence of NBS is dominated (more expensive and less
effective) by all NBS screening options considered. IRT–PAP
with an IRT cutoff at the 96th percentile is the most favorable
option with a ratio of CAD$28 432 per case of CF detected.
The next most favorable alternative is the IRT–IRT with an
IRT1 cutoff at the 96th percentile.
3.2. Sensitivity analyses
Results of univariate sensitivity analyses show that our
results are robust. The IRT–PAP with IRT1 N96th percentile
remains the most cost effective option with three exceptions.
Indeed, when the cost of PAP is set to CAD$15 per test or when
the sensitivity of PAP is 75%, the most cost effective option
becomes IRT96_IRT. When the cost of DNA analysis is set to
CAD$100, the IRT99.5_DNA_43mut is the most cost effective
option. In multivariate sensitivity analyses, IRT96_PAP and
IRT96_IRT remain the most cost-effective options. The proba-
bility of being the most cost effective option is 69.6% for
IRT–PAP and 21.7% for IRT–IRT.
4. Discussion
This study presents the comparison of the expected cost
effective of 20 NBS options and the absence of NBS under the
perspective of the Quebec health care system. This study was
justified on the basis that other modeling approaches [14–17]
have compared either a more limited number of screening
algorithms or have tested only one IRT cutoff level and/or a
limited CFTR mutation panel and didn't include the PAP
testing option.
Our results show that CF NBS dominates the absence of
NBS whatever the screening strategies considered. Among the
20 NBS algorithms tested (10 for IRT cutoff of 96th and 10 for
99.5th percentile), the IRT96_PAP strategy is the most cost
effective followed by the IRT96_IRT strategy. The cost per
additional case of CF detected by the IRT96_IRT strategy
compared to the IRT96_PAP strategy is CAD$49 653. All other
screening strategies are dominated by these two options, as they
are more expensive with no or little benefit in term of CF
detection. Indeed, at the end of the 5-year period, the total
number of children with CF diagnosed in each option is quitesimilar while the difference in costs is high thereby
disadvantaging options that include a DNA analysis as second
tier test. These options are also disadvantaged by the inclusion
of costs related to carrier identification (genetic counseling and
DNA analysis for parents). Finally, because they increase the
cost per case detected while not allowing to increase NBS case
detection over IRT–IRT and IRT–PAP options, options that
include DNA analysis as a 3rd tier test (25 or 43 mutations)
seem to be the less favorable options.
However, we recognize the limitation of using available data
on the use of PAP. This test has not been used in the Canadian
population, including Quebec. There are therefore uncertainties
regarding the applicability of data published from European
studies to our population. For example, the A455E mutation is
more common (around 3%) in Quebec [48] and has been
reported as a false negative for PAP results. This might change
the cost effectiveness of IRT–PAP and could advantage the
IRT–IRT option.
This study has other limitations. The main limitations of
such a simulation study are related to the mapping of a complex
reality [49,50]. Assumptions and simplifications have to be
made for some events for which it is difficult to obtain data. For
example, for cases missed by screening, we assumed the
same probability to be diagnosed clinically as for the “absence
of screening strategy”. We are aware that this might not
completely reflect the reality. For example, if the missed cases
by the NBS are more likely to be atypical cases that are difficult
to diagnose based on symptoms (pancreatic sufficient or
asymptomatic), the estimated costs per case detected might be
overestimated. On the opposite, if the majority of missed cases
are symptomatic, the estimated costs per case detected might be
underestimated. In the same way, our study did not model the
cost of management of family “emotional stress” related to the
fact that their child was not diagnosed early or was diagnosed
as a carrier. The model has not also considered the costs that
could be generated by the follow-up of atypical CF case
(CF related metabolic syndrome) detected by NBS. The
addition of these costs could increase the cost per case detected
by NBS. However, as these atypical CF cases are uncommon
and occur primarily in NBS algorithms involving DNA
detection, we believe that this would not change the ranking
order between options.
An additional limitation of this study has to do with the
validity of the parameters used in the simulation model.
Parameters were retrieved from an extensive literature search
and from experts' opinions. Yet, these parameters especially
those related to the performances of the NBS tests or the
efficacy of NBS may be specific to the populations under study
and might not apply totally to our population. However, we
believe that we addressed this issue by performing a large set of
sensitivity analyses, which showed that our results are robust.
Another limitation is related to the outcome considered
for this study. Indeed, we considered as the main outcome the
total number of cases of CF detected (i.e. identified through
screening or not). This might not be considered as the most
relevant outcome. Quality adjusted-life years (QALY) of the
children but also of their parents would certainly be more
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considered as the most relevant health outcome in the economic
evaluation field. A better survival and a better quality of life in CF
patients detected by newborn screening compared with patients
detected clinically are expected. However, an evaluation of
QALYs could not be performed, as there is no appropriate
instrument to measure utility scores in children under 5 years of
age [51,52].
A last limitation is related to the use of a single perspective,
i.e. the public healthcare perspective. The consideration of the
patient/family or societal perspectives could modify the ranking
of the options. For example, the addition of the patient/family
perspective could disadvantage options that include the second
IRT measurement, as an IRT2 measure needs a second blood
sample, hence a new contact with the healthcare system.
Despite these limitations, this study suggests that NBS
for cystic fibrosis is a cost-effective strategy compared to the
absence of NBS in our health care setting. The IRT–PAP
newborn screening algorithm with an IRT cutoff at the 96th
percentile is the most cost effective algorithm. Results consist
exclusively of cost effectiveness considerations. However, several
non-economic are taken into consideration when a decision on a
NBS program has to be made, such as laws, already existing
newborn screening programs, access to genetic counseling,
problem of carrier identification, etc. Nevertheless, besides the
fact that the IRT–PAP strategy is the most cost effective, it has
other advantages compared to other strategies. It is easy to
implement because the analysis is done on a single sample and it
allows avoiding the ethic difficulty of unwanted carrier's
identification. This CF screening strategy should therefore be
considered in any NBS screening program.
Finally, our results were produced in the Quebec context
(that is characterized by a quasi-exclusive public healthcare
system) and remain to be confirmed in other healthcare
jurisdictions especially where private insurance plans play a
major role.
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